» Articles » PMID: 32952338

Tumor Microenvironment in Primary Liver Tumors: A Challenging Role of Natural Killer Cells

Overview
Specialty Gastroenterology
Date 2020 Sep 21
PMID 32952338
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

In the last years, several studies have been focused on elucidate the role of tumor microenvironment (TME) in cancer development and progression. Within TME, cells from adaptive and innate immune system are one of the main abundant components. The dynamic interactions between immune and cancer cells lead to the activation of complex molecular mechanisms that sustain tumor growth. This important cross-talk has been elucidate for several kind of tumors and occurs also in patients with liver cancer, such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Liver is well-known to be an important immunological organ with unique microenvironment. Here, in normal conditions, the rich immune-infiltrating cells cooperate with non-parenchymal cells, such as liver sinusoidal endothelial cells and Kupffer cells, favoring self-tolerance against gut antigens. The presence of underling liver immunosuppressive microenvironment highlights the importance to dissect the interaction between HCC and iCCA cells with immune infiltrating cells, in order to understand how this cross-talk promotes tumor growth. Deeper attention is, in fact, focused on immune-based therapy for these tumors, as promising approach to counteract the intrinsic anti-tumor activity of this microenvironment. In this review, we will examine the key pathways underlying TME cell-cell communications, with deeper focus on the role of natural killer cells in primary liver tumors, such as HCC and iCCA, as new opportunities for immune-based therapeutic strategies.

Citing Articles

Global research trends in the tumor microenvironment of hepatocellular carcinoma: insights based on bibliometric analysis.

Han H, Zhao Z, He M, Guan G, Cao J, Li T Front Immunol. 2024; 15:1474869.

PMID: 39411719 PMC: 11473330. DOI: 10.3389/fimmu.2024.1474869.


Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy.

Dadgar N, Arunachalam A, Hong H, Phoon Y, Arpi-Palacios J, Uysal M Cancers (Basel). 2024; 16(18).

PMID: 39335203 PMC: 11429565. DOI: 10.3390/cancers16183232.


Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic model.

Yang D, Zhou Y, Zhang Y, Su Y, Shen J, Yu B Cancer Immunol Immunother. 2023; 72(12):4323-4335.

PMID: 38006433 PMC: 10992459. DOI: 10.1007/s00262-023-03567-4.


Heterogeneity of Cholangiocarcinoma Immune Biology.

Vita F, Olaizola I, Amato F, Rae C, Marco S, Banales J Cells. 2023; 12(6).

PMID: 36980187 PMC: 10047186. DOI: 10.3390/cells12060846.


Cancer Stem Cell and Hepatic Stellate Cells in Hepatocellular Carcinoma.

Quiroz Reyes A, Lozano Sepulveda S, Martinez-Acuna N, Islas J, Delgado Gonzalez P, Heredia Torres T Technol Cancer Res Treat. 2023; 22:15330338231163677.

PMID: 36938618 PMC: 10028642. DOI: 10.1177/15330338231163677.


References
1.
De Maria A, Bozzano F, Cantoni C, Moretta L . Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A. 2010; 108(2):728-32. PMC: 3021076. DOI: 10.1073/pnas.1012356108. View

2.
Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

3.
Llovet J, Hernandez-Gea V . Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014; 20(8):2072-9. DOI: 10.1158/1078-0432.CCR-13-0547. View

4.
Hudspeth K, Pontarini E, Tentorio P, Cimino M, Donadon M, Torzilli G . The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun. 2013; 46:55-65. DOI: 10.1016/j.jaut.2013.07.003. View

5.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View